Tyrosine-protein kinase BTK — Drug Target

All drugs that target Tyrosine-protein kinase BTK — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Kinase Inhibitor [EPC]

Marketed (2)

• Calquence · AstraZeneca · Kinase Inhibitor [EPC] · Oncology
  Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells.
• Brukinsa · Beigene Usa Inc · Kinase Inhibitor [EPC] · Oncology
  Brukinsa blocks the BTK protein, which is involved in the activation of B cells.